BioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments

MT Newswires Live06-16

BioMarin Pharmaceutical (BMRN) said Tuesday it presented new clinical data for its Voxzogo and BMN 333 treatments targeting hypochondroplasia and achondroplasia, both of which are growth-related bone conditions.

An investigator-led Phase 2 extension study showed that Voxzogo led to sustained growth improvements in children with hypochondroplasia, the company said.

The company intends to submit a supplemental New Drug Application to the US Food and Drug Administration during Q3 based on a separate Phase 3 study, it said.

Initial Phase 1 testing of BMN 333 in healthy adults demonstrated prolonged drug exposure supporting a weekly dosing schedule for achondroplasia, BioMarin Pharmaceutical said.

Patient enrollment for a Phase 2/3 study of the weekly drug began in April, with a data update from the dose-finding segment expected in 2027, the company added.

Price: 55.13, Change: -0.52, Percent Change: -0.93

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643234768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643234768","market":"us","top_or_hot":-1,"title":"BioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments","media":"MT Newswires Live","content":"<html><body><p> BioMarin Pharmaceutical (BMRN) said Tuesday it presented new clinical data for its Voxzogo and BMN 333 treatments targeting hypochondroplasia and achondroplasia, both of which are growth-related bone conditions.</p><p>An investigator-led Phase 2 extension study showed that Voxzogo led to sustained growth improvements in children with hypochondroplasia, the company said.</p><p>The company intends to submit a supplemental New Drug Application to the US Food and Drug Administration during Q3 based on a separate Phase 3 study, it said.</p><p>Initial Phase 1 testing of BMN 333 in healthy adults demonstrated prolonged drug exposure supporting a weekly dosing schedule for achondroplasia, BioMarin Pharmaceutical said.</p><p>Patient enrollment for a Phase 2/3 study of the weekly drug began in April, with a data update from the dose-finding segment expected in 2027, the company added.</p><p>Price: 55.13, Change: -0.52, Percent Change: -0.93</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-16 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BioMarin Pharmaceutical (BMRN) said Tuesday it presented new clinical data for its Voxzogo and BMN 333 treatments targeting hypochondroplasia and achondroplasia, both of which are growth-related bone conditions.</p><p>An investigator-led Phase 2 extension study showed that Voxzogo led to sustained growth improvements in children with hypochondroplasia, the company said.</p><p>The company intends to submit a supplemental New Drug Application to the US Food and Drug Administration during Q3 based on a separate Phase 3 study, it said.</p><p>Initial Phase 1 testing of BMN 333 in healthy adults demonstrated prolonged drug exposure supporting a weekly dosing schedule for achondroplasia, BioMarin Pharmaceutical said.</p><p>Patient enrollment for a Phase 2/3 study of the weekly drug began in April, with a data update from the dose-finding segment expected in 2027, the company added.</p><p>Price: 55.13, Change: -0.52, Percent Change: -0.93</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3581.USD","symbol_name":"Legg Mason ClearBridge - Value A Acc USD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643234768","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643234768","pubTimestamp":1781618646,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioMarin Pharmaceutical  said Tuesday it presented new clinical data for its Voxzogo and BMN 333 treatments targeting hypochondroplasia and achondroplasia, both of which are growth-related bone conditions.An investigator-led Phase 2 extension study showed that Voxzogo led to sustained growth improvements in children with hypochondroplasia, the company said.The company intends to submit a supplemental New Drug Application to the US Food and Drug Administration during Q3 based on a separate Phase 3 study, it said.Initial Phase 1 testing of BMN 333 in healthy adults demonstrated prolonged drug exposure supporting a weekly dosing schedule for achondroplasia, BioMarin Pharmaceutical said.Patient enrollment for a Phase 2/3 study of the weekly drug began in April, with a data update from the dose-finding segment expected in 2027, the company added.Price: 55.13, Change: -0.52, Percent Change: -0.93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4139":"生物科技","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BMRN.AU":"Ballymore Resources Ltd","BK7095":"多种金属与采矿","BK4566":"资本集团","BMRN":"拜玛林制药","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BMN":"BlackRock 2037 Municipal Target Term","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"translate_title":"拜玛林制药公布3年Voxzogo数据、BMN 333早期生长障碍治疗结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":1,"BMRN.AU":1,"BMN":1.5},"content_text":"BioMarin Pharmaceutical (BMRN) said Tuesday it presented new clinical data for its Voxzogo and BMN 333 treatments targeting hypochondroplasia and achondroplasia, both of which are growth-related bone conditions.An investigator-led Phase 2 extension study showed that Voxzogo led to sustained growth improvements in children with hypochondroplasia, the company said.The company intends to submit a supplemental New Drug Application to the US Food and Drug Administration during Q3 based on a separate Phase 3 study, it said.Initial Phase 1 testing of BMN 333 in healthy adults demonstrated prolonged drug exposure supporting a weekly dosing schedule for achondroplasia, BioMarin Pharmaceutical said.Patient enrollment for a Phase 2/3 study of the weekly drug began in April, with a data update from the dose-finding segment expected in 2027, the company added.Price: 55.13, Change: -0.52, Percent Change: -0.93","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643234768","isCrawlerRequest":true}